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A B S T R A C T
Objectives: Information on dengue in Africa is limited. To estimate the proportion of dengue-positive
cases among febrile patients and describe clinical indicators of dengue, we conducted passive health
facility-based fever surveillance in Mombasa, Kenya.
Methods: Non-malarial febrile patients between one and 55 years were enrolled at three health facilities
between March 2016 and May 2017. Acute and convalescent blood samples were collected with an
interval of 10–21 days. Acute samples were tested with dengue RDT and a selected subset with RT-PCR,
and acute/convalescent samples with IgM/IgG ELISA.
Results: Among 482 enrollees, 295 (61.2%) were dengue-positive based on laboratory results. The
surveillance covered the beginning of a dengue outbreak in April-May 2017, during which 73.9% of
enrollees were dengue-positive. By contrast, during the non-outbreak period, 54.6% were dengue-
positive. Dengue case status was positively associated with rash, fatigue, headache, retro-orbital pain,
nausea/vomiting, nose bleeding, gum bleeding, loss of appetite, myalgia, and arthralgia. Dengue-positive
cases in our study had mostly mild disease, with only two requiring observation, and no DHF.
Conclusions: The clinical response was generally mild relative to what was observed in SE Asia and the
Americas. Given the high level of DENV transmission in Mombasa, more data would be needed to further
understand the disease burden and improve case detection for surveillance/monitoring of outbreaks.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(http://creativecommons.org/licenses/by/4.0/).(DENVs; serotypes 1–4) and is a major and rapidly increasing
global public health problem (Boisier et al., 1994). Recent studies
have estimated an annual incidence of 50–100 million symptom-
atic infections globally, with 50,000 dengue hemorrhagic fever
(DHF) cases requiring hospitalization and approximately 20,000
deaths annually (Bhatt et al., 2013; World Health Organization,
2009; Halstead, 1988; Gubler, 1999; Singhi et al., 2007).
Despite the documented presence of Aedes mosquitoes and
dengue cases in Africa, most reports have come from a small
number of countries, with few prospective and population-based
studies (Surtees, 1967; Kamgang et al., 2013; Messina et al., 2014;
Amarasinghe et al., 2011; Kraemer et al., 2015; Baba et al., 2016).
With many competing public health problems, the clinical
presentation of dengue is non-specific and difficult to distinguish
















































208 J.K. Lim et al. / International Journal of Infectious Diseases 100 (2020) 207–215diagnostic assays not widely available (Were, 2012). Also, unlike
many countries in Asia and Latin America, most African countries
lack systems of mandatory reporting of dengue cases (Beatty et al.,
2010).
In Kenya, compared to other African countries, there is some
evidence on dengue, with several documented epidemics and
outbreaks in different locations. The most recent outbreak
reported was from Mombasa in May 2017 (World Health
Organization, 2017). In 2011, an outbreak was confirmed in
Mandera, North Eastern Region, and, in 2013, another in Mombasa
continuing into 2014 (Ellis et al., 2015; Obonyo et al., 2018). In
addition to outbreak investigations, a study based on 868 febrile
patients, identified from September 2011 to December 2014 in
multiple locations in Kenya, reported 40% (345/868) to be dengue-
positive by either IgM enzyme-linked immunosorbent assay
(ELISA) or by RT-PCR (Konongoi et al., 2016).
In terms of seroprevalence, in 2016–2017, a study conducted in
rural Taita–Taveta County and urban slums of Kibera, Nairobi,
tested 560 samples from febrile patients for DENV IgM, IgG, and
NS1 antigen (Masika et al., 2020). The study found IgG
seroprevalence to be 3.5% in Nairobi and 14.6% in Taita–Taveta,
confirming local transmission in this part of rural Kenya (Masika
et al., 2020). Between 2010 and 2011, a hospital-based cross-
sectional survey was conducted in Western Kenya among children
aged 12 years and under (Inziani et al., 2020). Of 656 children, 1%,
9%, and 20% tested positive by indirect ELISA for DENV 1, 2, and 3,
respectively (Inziani et al., 2020). Also, dengue was retrospec-
tively found to be the most common viral pathogen in HIV-
negative samples from the 2007 Kenya AIDS Indicator Survey,
with 12.5% having dengue IgG (Ochieng et al., 2015). Similarly, a
household survey in Mombasa reported 13% with serological
(IgM) evidence of either past or current DENV infection. While
such information suggests a notable dengue transmission in
Kenya, its magnitude remains mostly unknown (Ellis et al., 2015;
Ochieng et al., 2015).
Methods
Site selection
Site selection was based on available data in the published
literature as well as available research infrastructure (Messina
et al., 2014; Lim et al., 2018; Brady et al., 2012), after consultation
with local collaborators from the Kenya Medical Research Institute
(KEMRI) and the Ministry of Health of Kenya. Ganjoni health center,
Tudor sub-county Hospital, and Coast Provincial General Hospital
(CPGH) were selected, serving a catchment population of 74,735
residents in Mombasa (Figure 1) (Lim et al., 2018; Central
Intelligence Agency, 2020; Wikipedia, 2020).
In the 6-level system of healthcare service delivery in Kenya,
Ganjoni health center is a Kenya Essential Package for Health
(KEPH) level 2 health service provider, focusing on primary care
and health promotion for the community. Tudor sub-county
Hospital is KEPH level 4, district-level health center with
outpatient and observation care, and CPGH is KEPH level 5, the
largest tertiary referral hospital in the entire coastal region.
Study area and population
Coastal Kenya, in eastern Africa, has a warm and humid tropical
climate (Wikipedia, 2020). Mombasa has a population of about 1.3
million, of whom almost 50% are under 15 years of age (Singhi
et al., 2007; Central Intelligence Agency, 2020). The “long rains”
period begins around April and the “short rains” around October
(Wikipedia, 2020). This study took place between March 2016 and
May 2017 (15 months).Study design
Investigational methods used in this study have previousl
been described (Lim et al., 2018). To estimate the proportion o
dengue cases among non-malarial febrile patients, and compar
their clinical and epidemiologic patterns to non-dengue febril
patients, the Dengue Vaccine Initiative (DVI), in collaboration wit
KEMRI and the Ministry of Health of Kenya, conducted passiv
health facility-based fever surveillance in Mombasa, Kenya. In bot
outpatient and inpatient departments at the three selecte
facilities, patients who were febrile or with a history of fever i
the past seven days were tested for malaria using RDT (eithe
CareStart Malaria or SD BIOLINE Malaria kit) as part of routin
practice. Those malaria RDT-negative patients who were eligibl
(see below) and agreed to participate were enrolled (Figure 2
They were tested with the SD BIOLINE Dengue Duo RDT kit, whic
detects both the dengue virus NS1 antigen and antibodies (dengu
IgG/IgM). An acute sample of blood was taken at first presentatio
(visit 1). A study physician conducted interviews and physica
examinations, and the surveillance case report form was complet
ed to capture medical history, with demographic information
symptoms, and laboratory results (Lim et al., 2018).
The patient was asked to return to the facility for th
convalescent sample collection 1014 days after the first visi
After the 14th day, if the patient had not returned, a house visit wa
made to collect the second blood sample within 21 days of visit 1
Study participants
Individuals who met the following criteria were eligible fo
study enrollment:
1 Age 1–55 years;
2 Resident (for 12 months) of the catchment area;
3 Signed written informed consent from all adult subjects;
4 Written assent for those aged between 13–17 years wit
informed consent by a parent or guardian of any chil
participant;
5 Patients presenting with current fever (body temperatur
37.5 C) or history of fever for 7 days duration without localizin
signs (fever caused by a localized infection or with known etiolog
other than dengue, such as malaria-positive  by RDT).
Laboratory testing algorithm
Acute samples were tested using a commercial RDT for dengu
NS1 antigen and IgM/IgG (Dengue Duo, Standard Diagnostics
Yongin-Si, Korea) on the first visit at the facility (day 1). All acut
and convalescent samples were subsequently tested in the KEMR
laboratory using commercial dengue IgM/IgG ELISA kits (SD
Dengue IgM/IgG Capture ELISA, Standard Diagnostics, Yongin-S
Korea). The results from IgM/IgG ELISA and RDT were used to selec
those samples that would be further tested. Those samples tha
met the following criteria underwent molecular analysis with RT
PCR (Alm et al., 2015): (i) NS1- and/or IgM-positive on the rapi
test in the acute phase; and/or (ii) seroconverted between acut
and convalescent phases on IgM and IgG capture ELISA. RT-PCR wa
also performed on a limited number of randomly selected sample
that were seropositive at both acute and convalescent time point
by IgM/IgG capture ELISA, as well as those seronegative by RDT an
IgM/IgG ELISA at all time points. In addition, all convalescen
samples were tested using commercial chikungunya IgM ELISA ki
(SD Chikungunya IgM ELISA, Standard Diagnostics, Yongin-S
Korea). The detailed laboratory testing procedure has bee
previously described (Lim et al., 2018).
Figure 1. A map of the area of catchment population and study facilities.
Notes: The map shows the approximate location of the three selected study facilities (Ganjoni health center, Tudor sub-county Hospital, and Coast Provincial General
Hospital), covering the catchment area population of residents of Mvita sub-county, Mombasa, Kenya. Source: (Lim et al. (2018)).
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according to WHO diagnostic criteria (World Health Organization,
2012). Sero-conversion of anti-dengue IgM and IgG between the
acute and convalescent phases and/or virus detection (RT-PCR) in
the acute serum specimen was considered to be confirmed dengue.
A positive IgM serology in single serum and/or positive on NS1 or
IgM of RDT in single acute serum were criteria for probable dengue
infection (World Health Organization, 2012). Confirmed and
probable dengue infections were grouped to be dengue-positive
in this analysis. Samples with negative results on RT-PCR and
seronegative results on paired IgM/IgG ELISA results were
classified as non-dengue. A positive IgG serology in a single
serum, with negative results from all other tests, was classified as
non-dengue.
Statistical analysis
A descriptive summary of characteristics is presented for
dengue-positive versus non-dengue cases. Body temperature
38.0 C, the 75th percentile of the body temperature measured
at the time of enrollment, was used to create a dichotomousvariable (i.e., <38.0 C vs.  38.0 C). Clinical diagnosis at
admission, prior to lab-confirmation, was categorized as suspected
dengue, undifferentiated fever, and non-dengue. Yellow fever
vaccination history was dichotomized between those who
reported having been vaccinated versus those who did not
remember or reported no vaccination.
In April 2017, we observed a steep rise in the dengue caseload in
the study facilities. Mombasa County health officials issued a
public health alert over a dengue outbreak, and it was declared an
outbreak in May (Impouma, 2017; Githeko, 2017; Sanga, 2017;
Onsarigo, 2017). The last two months of surveillance were grouped
as an outbreak period and the previous months as non-outbreak.
Categorical comparisons were made across dengue status using χ2
or Fisher’s exact tests. Continuous variables were compared using
Student’s t-test or ANOVA. All analyses were performed using SAS
version 9.4 (SAS Institute, Cary, North Carolina).
Ethical considerations
The study protocol obtained ethical approval from the



















Figure 2. Patient flow in the passive fever surveillance at the study facilities.
Notes: The chart shows the flow of patients from screening, enrollment to study participation, with determination of laboratory-based status of dengue infection, as well as
how the analysis sample was reached.
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the ethical review committee of CPGH, and the KEMRI Scientific
and Ethical Review Unit.
Results
General characteristics of subjects
Of 513 enrolled individuals, 31 had incomplete visit 1 (acute) lab
data (i.e., RDT results available but no sample for ELISA or PCR,
Figure 2). These patients were similar to those in the analysis
sample in terms of age, gender, days into illness at the time of
enrollment, and whether or not they were kept under observation.
The analysis sample includes 482 patients. Close to 80% of the
dengue-positive patients were between 15 and 34 years (Table 1).
Laboratory-based confirmation of dengue cases
The breakdown by 3-level dengue status (dengue-confirmed,
probable, and non-dengue) is presented in the supplementary
table (table S1). Table 1 describes the demographic and clinical
characteristics between non-dengue and dengue-positive cases
with dengue-confirmed and probable combined (i.e., the 2-level
status). Of 482 patients in the analysis sample, 46% (n = 223) had
confirmed dengue infections based on paired ELISA and/or PCR.
There were 15% (n = 72) classified as dengue-probable, based onRDT and/or ELISA seropositivity, and 39% (n = 187) as non-dengu
cases (Figure 2). Of these dengue-positive cases, 69% (205/295
were based on PCR confirmation (Figure 2). Also, 28% (48 of 17
paired samples tested) and 24% (40 of 167 paired samples tested
were lab-confirmed with dengue infection by seroconversio
between acute and convalescent samples using IgM and IgG
capture ELISA. There were 32 patients confirmed by both PCR an
ELISA (either IgM or IgG seroconversion) and 18 patients b
seroconversion on ELISA alone.
Of the 482 RDT results, 39% (n = 189) were positive for NS1 and
or IgM. In terms of clinical diagnosis, 63% (186/295) of dengue
positive patients had clinically suspected dengue prior to lab
confirmation.
We retrospectively performed chikungunya IgM ELISA tests o
all the convalescent samples; none were found to be chikunguny
positive.
Dengue serotypes during the outbreak and non-outbreak periods
There were peaks of dengue incidence in April-June 2016 an
April-May 2017 (Figure 3), coinciding with the “long rains” season
Of 295 dengue cases in the analysis sample of 482 patients, 17
were identified before (173/317), and 122 during the outbrea
(122/165). DENV-2 was the predominant serotype before an
during the outbreak, with DENV-1 remaining at lower level
throughout the study period (Figure 3).
Table 1
Demographic and clinical characteristics between dengue-positive and non-dengue cases among febrile enrollees of the health facility-based fever surveillance in Mombasa,
Kenya in 2016-2017.
Characteristics Dengue-positive (n = 295) No. (%)* Non-dengue (n = 187) No. (%)* Total (n = 482) No. (%)* p-value
Place of enrollment 0.645
CPGH 139 (47.12) 94 (50.27) 233 (48.34)
Tudor 123 (41.69) 70 (37.43) 193 (40.04)
Ganjoni 33 (11.19) 23 (12.30) 56 (11.62)
Mean age (SD) 23.35 (9.23) 23.14 (13.46) 23.27 (11.05) 0.839
Age group (years) <.001
14 8 (2.71) 31 (16.58) 39 (8.09)
59 10 (3.39) 6 (3.21) 16 (3.32)
1014 13 (4.41) 6 (3.21) 19 (3.94)
1519 45 (15.25) 21 (11.23) 66 (13.69)
2024 124 (42.03) 39 (20.86) 163 (33.82)
2534 61 (20.68) 44 (23.53) 105 (21.78)
3544 24 (8.14) 28 (14.97) 52 (10.79)
4555 10 (3.39) 12 (6.42) 22 (4.56)
Female 117 (39.66) 90 (48.13) 207 (42.95) 0.067
Required observation/Outpatients 2 (0.68)/293 (99.32) 0/187 (100.0) 2 (0.41)/480 (99.59) 0.259
Fever duration prior to visit (mean days, SD) 2.96 (1.92) 2.84 (1.79) 2.91 (1.87) 0.513
Fever duration, entire illness (mean days, SD)** 6.88 (3.75) 4.91 (2.76) 6.17 (3.55) <.001
Mean temperature at presentation (SD) 37.85 (0.66) 37.71 (0.73) 37.80 (0.69) 0.024
Temperature at presentation 0.014
Below 38.0c 179 (60.68) 134 (71.66) 313 (64.94)
38.0c 116 (39.32) 53 (28.34) 169 (35.06)
Prev. dengue infection 3 (1.02) 3 (1.60) 6 (1.24) 0.323
YF vaccination 146 (49.49) 77 (41.18) 223 (46.27) 0.074
Clinical diagnosis
Suspected dengue 186 (63.05) 18 (9.63) 204 (42.32) <.001
Undifferentiated fever 76 (25.76) 121 (64.71) 197 (40.87)
Non-dengue 33 (11.19) 48 (25.67) 81 (16.80)
URI 18 (54.55) 27 (56.25) 45 (55.56)
Malaria 1 (3.03) 3 (6.25) 4 (4.94)
UTI 2 (6.06) 2 (4.17) 4 (4.94)
Others 12 (36.36) 16 (33.33) 28 (34.57)
Signs and symptoms (presence)
Rash 34 (11.53) 10 (5.35) 44 (9.13) 0.022
Fatigue/weakness 269 (91.19) 156 (83.42) 425 (88.17) 0.010
Headache 282 (95.59) 155 (82.89) 437 (90.66) <.001
Retro-orbital pain 166 (56.27) 69 (36.90) 235 (48.76) <.001
Neck pain 90 (30.51) 43 (22.99) 133 (27.59) 0.072
Ear pain 23 (7.80) 10 (5.35) 33 (6.85) 0.300
Nasal congestion 15 (5.08) 26 (13.90) 41 (8.51) 0.001
Rhinorrhea 27 (9.15) 37 (19.79) 64 (13.28) 0.001
Sore throat 17 (5.76) 22 (11.76) 39 (8.09) 0.019
Cough 46 (15.59) 48 (25.67) 94 (19.50) 0.007
Sputum production 9 (3.05) 15 (8.02) 24 (4.98) 0.015
Nausea & vomiting 151 (51.19) 75 (40.11) 226 (46.89) 0.018
Diarrhea 31 (10.51) 25 (13.37) 56 (11.62) 0.340
Constipation 13 (4.41) 9 (4.81) 22 (4.56) 0.835
Abdominal pain 101 (34.24) 55 (29.41) 156 (32.37) 0.270
Nose bleeding 8 (2.71) 0 8 (1.66) 0.026
Gum bleeding 10 (3.39) 0 10 (2.07) 0.008
Flushed face 6 (2.03) 5 (2.67) 11 (2.28) 0.647
Loss of appetite 195 (66.10) 93 (49.73) 288 (59.75) <.001
Myalgia 221 (74.92) 114 (60.96) 335 (69.50) 0.001
Arthralgia 222 (75.25) 104 (55.61) 326 (67.63) <.001
* unless noted otherwise.
** only among those that reported the end of fever illness (n = 309; 199 dengue and 110 non-dengue patients).
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Only two of the 482 patients required observation, both for less
than three days, and both were dengue-positive. Of the 482
patients, the average time between fever onset and presentation
was 3.0 days, with no evidence that this differed between dengue-
positive and non-dengue cases. However, the average entire
duration of fever illness was significantly longer for dengue cases
than non-dengue cases — 6.9 versus 4.9 days — among 309 patients
with data on the endpoint of their fever illness duration.
Of the non-dengue patients, 64.7 and 25.7% were clinically
diagnosed with undifferentiated fever and non-dengue, respec-
tively. Regarding symptoms, rash, fatigue, headache, retro-orbitalpain, nausea/vomiting, nose bleeding, gum bleeding, loss of
appetite, myalgia, and arthralgia were found more commonly
among dengue-positive cases, compared to non-dengue.
Discussion
Overall, evidence about dengue in Africa is limited (Amar-
asinghe et al., 2011) and is mostly from outbreak investigations and
retrospective testing of existing serum banks from other studies
(Ellis et al., 2015; Obonyo et al., 2018), although, among African
countries, Kenya has relatively more evidence (Ellis et al., 2015;
Obonyo et al., 2018; Konongoi et al., 2016; Masika et al., 2020;






























Figure 3. Monthly distribution of the enrolled febrile patients and patients by dengue status as well as serotype distribution.
Notes: The figure has two parts. Panel A: monthly distribution of dengue-positive and non-dengue cases among the enrolled patients; Panel B: % of serotype composition
(numbers shown in the bars) by month.
212 J.K. Lim et al. / International Journal of Infectious Diseases 100 (2020) 207–215dengue infection is an important cause of non-malarial febrile
illness in patients seeking care at public health facilities and adds
to the available literature on the endemicity of dengue in
Mombasa.
General and clinical characteristics of dengue cases
Our study’s key finding was that a substantial number of
dengue-positive cases was identified in Mombasa, during an
outbreak in Apr/May 2017, as well as the notable baseline caseload
even in the non-outbreak period. Of 482 non-malarial febrile
patients, 61.2% were identified as dengue-positive. Of those
patients enrolled before the outbreak, approximately half
(54.6%) were dengue-positive compared to more than two-thirds
during the outbreak (73.9%). Shown in Figure 3 as a steep slant in
caseload, our study was only able to capture the start of the
outbreak in April and May; an alert over the outbreak was first
reported by media in early May (Impouma, 2017; Sanga, 2017;
Onsarigo, 2017). Officially reported to WHO, although in May and
June 2017, the estimate was similar to our study; more than half of
the individuals included (540/945) were lab-confirmed with
dengue during this outbreak in Mombasa (World Health Organi-
zation, 2017).
Among comparable previous studies, few reported levels of
dengue as high as this study (Obonyo et al., 2018). In particular, a
hospital-based surveillance study conducted in Mombasa in 2013
found that, among 267 cases with suspected dengue, 58% were lab-
confirmed with a current infection (Ellis et al., 2015). In our data, of
204 dengue-suspected patients, 156 (76%) were dengue-confirmed
by either PCR and/or ELISA (suppl. Table 1). There may be
differences in study settings, but these still indicate similarly high
proportions of dengue cases.On the other hand, most other published findings differ from
ours. One study reported 15% of 500 febrile patients identified i
CPGH from January 2014 to March 2015 to be DENV-confirmed
based on in-house indirect ELISA and Focus Reduction Neutraliza
tion tests (FRNT), even without screening out malaria RDT-positiv
cases (Munyuga et al., 2016). A study conducted in Kilifi, on th
coast 70 km north of Mombasa, reported that 10% of febrile adult
who had neither acute HIV infection nor malaria (by RDT) wer
PCR-confirmed with dengue in 2014–2015 (Ngoi et al., 2016
Among the corresponding subgroup in our study, 173 (50.4%
dengue cases were confirmed by either PCR and/or ELISA amon
343 febrile patients between 18 and 35 years old. Even if w
consider the differences in the study setting and methods, th
estimate of the proportion with dengue was higher in our data.
During the study period, there was a programmatic challenge t
patient recruitment due to a strike among medical officers for 7
days between September and November of 2016. Health facilitie
remained operational with other staff, but the official absence o
medical officers at facilities could have influenced health-seekin
behavior, and our surveillance might otherwise have enrolled 
larger volume of febrile patients. If so, our denominator of non
malarial fever cases could have been bigger, and the proportion o
dengue before the outbreak could have been lower.
Chikungunya virus was suspected to be one of the possibl
co-circulating pathogens in the area (Heath et al., 2020). To see
co-infections with dengue, we retrospectively performed chikun
gunya IgM ELISA tests on all the convalescent samples; none wa
found positive. Furthermore, our study did not enroll malaria RDT
positive patients in the screening process. This may be a limitatio
to the study, as some of them could have had co-infection wit
dengue. The review by Stoler et al. also highlighted th
overdiagnosis of malaria among febrile episodes and supporte
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based on the available literature (Stoler et al., 2014). However, a
study of the 2011 dengue outbreak in Mandera town, Kenya,
reported four out of 30 lab-confirmed dengue cases to have malaria
co-infection (Obonyo et al., 2018). In 2014–2015, a study tested sera
from 385 febrile children in four study sites in Kenya using
microscopy and real-time molecular assays for DENVs, chikungu-
nya virus, malaria, and Leptospira (Waggoner et al., 2017). While 15
patients had coinfections- with P. falciparum and CHIKV, none had
co-infection with malaria and dengue (Waggoner et al., 2017). Also,
Amoako et al. reported one case of malaria and dengue co-infection
out of 166 children with AFI in Ghana, where malaria is the
predominant disease (Amoako et al., 2018). Overall, based on the
available literature, such concurrent infection is reported to be
uncommon (Wiwanitkit, 2011; Epelboin et al., 2012).
In terms of symptoms, dengue cases were associated with rash,
fatigue, headache, retro-orbital pain, nausea/vomiting, nose
bleeding, gum bleeding, loss of appetite, myalgia, and arthralgia,
compared to non-dengue. These were also reported as being
positively associated with dengue in other studies, including a
surveillance study of the 2011 dengue outbreak in Mandera, Kenya
(Obonyo et al., 2018; Guo et al., 2017; Humayoun et al., 2010;
Hotchandani, 2014; Medina et al., 2011; Low et al., 2006; Ahmed
et al., 2008).
Dengue serotypes during outbreak and non-outbreak periods
In our study covering 2016–2017, DENV-2 was the predominant
serotype both before and during the outbreak (Figure 3). A study of
febrile patients in CPGH from January 2014 to March 2015 also
reported DENV-2 as the predominant serotype, followed by DENV-
3 and DENV-1 (Munyuga et al., 2016), as did a study of the
outbreaks in 2013–2014 and 2017 based on sequencing results
(Langat et al., 2020). Although not observed in this study,
outbreaks may coincide with a shift in dengue serotypes (Bennett
et al., 2010; Gubler, 1998; Saha et al., 2016), and earlier reports,
covering the times prior to DENV-2 in circulation, support DENV-1
to be the prevalent serotype in Kenya. In Mombasa, between 2011
and 2014, including the 2013 outbreak, the most frequent serotype
was DENV-1, followed by DENV-3 (Konongoi et al., 2016; Koech,
2015). DENV-1 was the prevalent serotype in circulation in March
and April 2016 in a cohort of children in Western Kenya, in Kisumu
and Chulaimbo (Vu et al., 2017). DENV-2 may have partially
replaced DENV-1 prior to our study. However, it is difficult to
determine whether there were virological differences between
outbreak and non-outbreak periods without detailed information
on virus strain.
Mild case profile
Most of our dengue-positive cases were mild. Only two cases
required observation for two days (discharged the day after
admission), and both were dengue-positive. Both were clinically
diagnosed with dengue, not DHF, and no complications were
recorded. Our study did not collect data on other indicators of
dengue severity. No patient reported hemorrhagic signs, with few
patients reporting warning signs of severe dengue.
Although disease severity may be associated with secondary
dengue infection, due to small numbers, this study could not draw
meaningful conclusions in clinical differences between primary
and secondary dengue cases. Among 163 cases with both IgM and
IgG ELISA results available on paired sera, ten cases, all
outpatients with ages ranging from 14 to 42 years, were likely
secondary infections based on IgM seroconversion from acute to
convalescent samples with IgG seropositivity (Cordeiro et al.,
2009).Clinical responses depend on several factors (Halstead, 2019),
including age and exposure to a heterotypic virus. It is commonly
reported for dengue patients to have outcomes with warning signs
or severe dengue, and often they are associated with young age
(<10 years) (Burattini et al., 2016; Halstead, 2006) or among the
elderly population with underlying diseases (Huy et al., 2019) in
other known dengue-endemic regions. However, there are limited
data from Kenya and Africa on how dengue affects different age
groups.
Among those attending the study facilities in this study, dengue
cases were concentrated between 15–34 years of age, and this
reflects the enrollment rate also being concentrated in the same
age groups and the age structure of the population. About 45% of
Mombasa residents are aged between 10–29 years, 31% over 30
years, and about 24% under ten years (ICT Authority, 2009).
Nonetheless, the observed high proportion of dengue-positive
cases in teenagers and young adults was higher on average than in
the 2011 outbreak in Mandera, in which 30% of dengue cases were
under ten years old with another 20% between 10–19 years
(Obonyo et al., 2018). This was also consistent with data from
Sudan, in which 73% of clinically diagnosed DHF cases in 2005 were
between 5–15 years of age (Malik et al., 2011). However, given the
youth of Mombasa’s age structure, our data, based on enrollment
skewed to a younger population, are not sufficient to determine
dengue epidemiology patterns with respect to the age, generaliz-
able to the entire country.
The mildness of dengue disease may be due to protective
genetic variants (Jaenisch et al., 2014). There is evidence from Cuba
that the expression of specific genes is associated with severity
(Sierra et al., 2017). Although our study did not seek to record race
or ethnicity, 95% of Kenyans self-identify with an ethnic group
associated with the Nilo-Saharan (Nilotic), Cushitic or Bantu
language families (Kenya national bureau of statistics, 2013;
Campbell and Tishkoff, 2008). Bantu ethnic groups are likely to be
genetically closer to the West African ancestors of most Afro-
Cubans (Sierra et al., 2017). Since there is a considerable genetic
variation between Africans (Yu et al., 2002), either the same or
other genes may be responsible for the lower risk of dengue in
black Africans observed in Tanzania (Boillat-Blanco et al., 2018). In
any case, such genetic factors, associated with race, may help
explain our findings of dengue as a mild disease in native residents
of Mombasa.
While there are data supporting a reduced risk of severe dengue
in Africa (Jaenisch et al., 2014; Boillat-Blanco et al., 2018), there
have been reports of severe dengue cases. During a dengue
epidemic in the urban parts of Senegal in 2009, 196 of 696 serum
samples were dengue-confirmed; there were 31 hospitalizations,
five DHF, and one fatal case of DSS (Faye et al., 2014). In Sudan, one
paper reported 81 IgM-based dengue-confirmed patients in 2010,
classifying 58% of them as DHF and 11% as DSS using the WHO
criteria (Abdallah et al., 2012). Another paper based on the 2005
DHF outbreak in Sudan reported 312 cases hospitalized with
clinically diagnosed DHF with 11.9% DSS and a 3.8% mortality rate
among patients, with most between 5–15 years of age (Malik et al.,
2011). Nonetheless, this is largely understudied in Africa, with the
currently available data focused on either Senegal or Sudan.
Study limitations and strengths
Dengue transmission can vary substantially over time and
space. In endemic areas, dengue epidemics occur at between three
and 5-year intervals (Bennett et al., 2010). Hence, the generaliz-
ability of our study is limited by its duration of 15 months and
geographical restriction to one area of the Mvita sub-county.
Furthermore, one source of bias could be due to the study design,
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providers other than the study facilities, including private clinics.
This may further restrict the generalizability of the findings.
Nonetheless, our study held several strengths. By implementing
the surveillance at three different KEPH levels of public health
facilities, we were able to capture patients seeking care at various
levels of healthcare service. Unlike previous reports in Kenya
focusing mostly on outbreaks, this study captured the time before
the outbreak as well as the first two months of the outbreak, with a
large sample size and high dengue caseload, enabling an
exploration of the differences between dengue and non-dengue
cases (Figure 3) (Impouma, 2017; Sanga, 2017; Onsarigo, 2017).
Conclusion
Our data provide evidence for a high level of transmission of
dengue in Mombasa and demonstrate the magnitude of the
dengue caseload during the 2017 outbreak and during the non-
outbreak period. Almost all of our dengue cases were mild.
Nonetheless, given the repeated outbreaks and endemicity of
DENV transmission in Kenya, there should be improved case
detection, clinical diagnosis in the clinical setting, and strength-
ened monitoring of dengue outbreaks. Furthermore, more data are
needed to document clinical and epidemiologic patterns of dengue
in Africa, which may differ from those in Southeast Asia and the
Americas.
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